## **Application and Contract for Clinical Trials Directory**

Directories will be accessible July 2022 through June 30, 2023.



## **Step 1: Contact Information**

Company Name			
Contact	т	itle	
Phone (direct only)		_ Mobile	
Email (direct only)		Website	
Address			
City	State 2	<u>Zip</u>	_ Country
☐ I would like to receive communication opt out of receiving these messages at a			unities at current and future ASCO meetings. To $\underline{\mathbf{n}}$ .
Step 2: Clinical Trials Directory O (Clinical Trials listing Compound/Device N		ollowing page)	View Directory Details
☐ Clinical Trials Directory – \$10,000 Pe	r Listing		
Total # of Listings:	Total Discount/Fee*: \$		Total Cost: \$
*Purchase three or more and get a 20% listing price.	discount on all listings. Non-ex	chibiting companies	may participate for a 20% premium fee above
	eting and returning items by the	e stated deadlines.	ory, including the confirmation and fulfillment All content is subject to ASCO approval. ASCO mpany contact to ensure the company's
Step 3: Payment and Cancellation  Deposit and Payment Schedule			ng information has changed. For updated ACH tions, email exhibitorservices@spargoinc.com.
For Applications Received On or Be		Make checks r	payable to: ASCO
By September 2, 2022	50% due	-	
By January 27, 2023	Remaining balance due	Mail check payment to: ASCO Exposition Management, c/o SPARGO, Inc. ◆ 11208 Waples Mill Road, Suite 112 ◆	
For Applications Received Beginning September 3, 2022		Fairfax, VA 220	J30
September 3, 2022-January 26, 2023		Credit Card Pa	yments: An invoice will be sent with instructions
Beginning January 27, 2023	100% due with application	to submit a credit card payment online. Credit cards will also be	
Cancellation Terms		accepted by pn	one at 703-631-6200 or 800-564-4220.
By September 1, 2022	100% refund	Submit applica	ation to: exhibitcontracts@spargoinc.com
September 2, 2022-January 26, 2023	50% refund	Need Help? Co	ontact: ascoexhibits@spargoinc.com
Beginning January 27, 2023	No refund	703-631-6200	
ASCO requires 50% payment no later than release the contracted or financial obligati			nuary 27, 2023. Failure to make payments does not out cause.
Step 4: Acknowledgement			
Furthermore, I have received, reviewed,	and agree that Company will oxhibits (as may be amended fr SPARGO, Inc., and official eve	comply with the Poli om time to time). C ent contractors relat	
Exhibitor Signature			Date
Printed Name	Telephone		

## Step 5: Clinical Trials Listing Compound (Drug) / Device Name (attach additional pages as needed)

Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	
Clinical Trials Listing – Compound (Drug) / Device Name:	